Streetbeat News

Stock Prices

DGX

Quest Diagnostics has updated its 2024 adjusted EPS forecast to a range of $8.80-$9.00, which is an increase from its prior guidance of $8.72-$8.97 and is above the consensus estimate of $8.86.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:59 am

KO

Coca-Cola shares are trading higher after the company reported better-than-expected Q2 results and raised its guidance.

Portfolio Pulse from Bill Haddad

July 23, 2024 | 10:58 am

KO

Coca-Cola expects its FY24 comparable EPS to grow by 5-6%, indicating a positive outlook for the company's financial performance in the upcoming fiscal year.

Portfolio Pulse from Bill Haddad

July 23, 2024 | 10:58 am

KO

Coca-Cola projects a 9-10% growth in organic revenue for FY24, but expects an 8-9% currency headwind to impact comparable EPS growth.

Portfolio Pulse from Bill Haddad

July 23, 2024 | 10:57 am

DGX

Quest Diagnostics has updated its 2024 net revenue forecast to a range of $9.5 billion to $9.58 billion, which is higher than its previous guidance of $9.4 billion to $9.48 billion and above the consensus estimate of $9.46 billion.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:57 am

PNR

Pentair (NYSE:PNR) reported Q2 2024 adjusted EPS of $1.22, beating the estimate of $1.14. Sales were $1.099 billion, surpassing the $1.095 billion estimate. This represents a 1.57% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:56 am

GPC

Genuine Parts (NYSE:GPC) reported Q2 2024 adjusted EPS of $2.44, missing the analyst estimate of $2.59. Sales were $5.963 billion, also missing the estimate of $6.047 billion. Despite the misses, sales increased by 0.81% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:56 am

KO

Coca-Cola (NYSE:KO) reported Q2 2024 earnings of $0.84 per share, beating the analyst estimate of $0.81. The company also reported sales of $12.4 billion, surpassing the $11.753 billion estimate. This represents a 3.58% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:55 am

MRK

Merck announced that its prophylactic monoclonal antibody, Clesrovimab, for Respiratory Syncytial Virus (RSV) disease has met its primary safety and efficacy endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 10:52 am

CLRB

Cellectar Biosciences' Iopofosine I 131 has exceeded its primary endpoint in a pivotal study for Waldenstrom's Macroglobulinemia, achieving a 56.4% major response rate and a 98.2% disease control rate in heavily pretreated patients.

Portfolio Pulse from charles@benzinga.com

July 23, 2024 | 10:51 am